Bergau Leonard
Abteilung für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland.
Inn Med (Heidelb). 2024 Aug;65(8):755-761. doi: 10.1007/s00108-024-01743-x. Epub 2024 Jul 15.
Atrial fibrillation and heart failure are among the most common cardiovascular diseases and have a significant impact on the mortality and morbidity of affected patients. From a pathophysiological perspective, the two diseases are closely related and often perpetuate each other. Therefore, effective management of atrial fibrillation is now a central component of modern heart failure treatment. Based on current data, sinus rhythm should primarily be permanently maintained in patients with systolic heart failure. Catheter ablation has recently proven to be advantageous over purely pharmacological therapy and is therefore the treatment of choice for many patients with heart failure and atrial fibrillation. In patients with diastolic heart failure (heart failure with preserved ejection fraction [HFpEF]), the effect of catheter ablation is less clear. Data from randomized studies are urgently needed in order to further assess efficacy in this population.
心房颤动和心力衰竭是最常见的心血管疾病，对受影响患者的死亡率和发病率有重大影响。从病理生理学角度来看，这两种疾病密切相关且常常相互影响。因此，有效管理心房颤动现在是现代心力衰竭治疗的核心组成部分。根据目前的数据，收缩性心力衰竭患者应主要永久维持窦性心律。最近已证明导管消融比单纯药物治疗更具优势，因此是许多心力衰竭合并心房颤动患者的首选治疗方法。对于舒张性心力衰竭（射血分数保留的心力衰竭[HFpEF]）患者，导管消融的效果尚不清楚。迫切需要随机研究的数据，以便进一步评估该人群中的疗效。
